RVNC Revance Therapeutics Inc

Powering Prestige Experiences in Aesthetics with Products and Services Portfolio Revance Acquisition of May 19, 2020Powering Prestige Experiences in Aesthetics with Products and Services Portfolio Revance Acquisition of May 19, 2020

Forward-looking Statements / Safe Harbor / Market Data This presentation contains forward-looking statements which include, but are not limited to, statements regarding expected timing, completion and effects of the proposed transaction, the related benefits of the HintMD platform and related technologies to Revance and the combined business, market acceptance and opportunity, and the updated 2020 financial outlook and cash runway. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Revance’s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties related to: the ability of the parties to consummate the proposed transaction, satisfaction of closing conditions precedent to the consummation of the proposed transaction, potential delays in consummating the transaction and the ability of Revance to timely and successfully achieve the anticipated benefits of the transaction. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption “Risk Factors” and elsewhere in Revance’s most recent filings with the SEC, including Revance’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 and any subsequent reports on Form 10-K, Form 10-Q or Form 8-K filed with the SEC from time to time and available at www.sec.gov. These documents can be accessed on the Revance Investor Relations page at https://investors.revance.com/ by clicking on the link titled “Financials and Filings.” The risks and uncertainties may be amplified by the COVID-19 pandemic, which has caused significant economic uncertainty. The extent to which the COVID-19 pandemic impacts Revance’s and HintMD’s businesses, operations, and financial results, including the duration and magnitude of such effects, will depend on numerous factors, which are unpredictable, including, but not limited to, the duration and spread of the outbreak, its severity, the actions to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions can resume. The forward-looking statements included in this communication are made only as of the date hereof. Revance assumes no obligation and does not intend to update these forward-looking statements, except as required by law. ADDITIONAL INFORMATION AND WHERE TO FIND IT Revance plans to file with the SEC, and the parties plan to furnish to the investors of HintMD, a Registration Statement on Form S-4, which will constitute a prospectus of Revance and will include an information statement of HintMD, in connection with the proposed transaction. The prospectus/information statement described above will contain important information about Revance, HintMD, the proposed transaction and related matters. Investors are urged to read the prospectus/information statement carefully when it becomes available. Investors will be able to obtain free copies of these documents, and other documents filed with the SEC by Revance, through the website maintained by the SEC at www.sec.gov. In addition, investors will be able to obtain free copies of these documents from Revance by going to the Revance Investor Relations web page at https://investors.revance.com/ and clicking on the link titled “Financials and Filings” or by contacting Revance’s Investor Relations group at the following: Revance Therapeutics, Inc.:, Jeanie Herbert, 714-325-3584, jherbert@revance.com or Gilmartin Group, LLC.:, Laurence Watts, 619-916-7620, laurence@gilmartinir.com Participants in the Solicitation The respective directors and executive officers of Revance and HintMD may be deemed to be participants in the solicitation of written consents from the securityholders of HintMD in connection with the proposed transaction. Information regarding the interests of these directors and executive officers in the transaction described herein will be included in the prospectus/information statement described above. Additional information regarding Revance’s directors and executive officers is included in Revance’s proxy statement for its Annual Meeting of Stockholders, which was filed with the SEC on March 26, 2020. This document is available from Revance free of charge as described in the preceding paragraph. No Offer or Solicitation This communication is not intended to and shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote of approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended. 2Forward-looking Statements / Safe Harbor / Market Data This presentation contains forward-looking statements which include, but are not limited to, statements regarding expected timing, completion and effects of the proposed transaction, the related benefits of the HintMD platform and related technologies to Revance and the combined business, market acceptance and opportunity, and the updated 2020 financial outlook and cash runway. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Revance’s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties related to: the ability of the parties to consummate the proposed transaction, satisfaction of closing conditions precedent to the consummation of the proposed transaction, potential delays in consummating the transaction and the ability of Revance to timely and successfully achieve the anticipated benefits of the transaction. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption “Risk Factors” and elsewhere in Revance’s most recent filings with the SEC, including Revance’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 and any subsequent reports on Form 10-K, Form 10-Q or Form 8-K filed with the SEC from time to time and available at www.sec.gov. These documents can be accessed on the Revance Investor Relations page at https://investors.revance.com/ by clicking on the link titled “Financials and Filings.” The risks and uncertainties may be amplified by the COVID-19 pandemic, which has caused significant economic uncertainty. The extent to which the COVID-19 pandemic impacts Revance’s and HintMD’s businesses, operations, and financial results, including the duration and magnitude of such effects, will depend on numerous factors, which are unpredictable, including, but not limited to, the duration and spread of the outbreak, its severity, the actions to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions can resume. The forward-looking statements included in this communication are made only as of the date hereof. Revance assumes no obligation and does not intend to update these forward-looking statements, except as required by law. ADDITIONAL INFORMATION AND WHERE TO FIND IT Revance plans to file with the SEC, and the parties plan to furnish to the investors of HintMD, a Registration Statement on Form S-4, which will constitute a prospectus of Revance and will include an information statement of HintMD, in connection with the proposed transaction. The prospectus/information statement described above will contain important information about Revance, HintMD, the proposed transaction and related matters. Investors are urged to read the prospectus/information statement carefully when it becomes available. Investors will be able to obtain free copies of these documents, and other documents filed with the SEC by Revance, through the website maintained by the SEC at www.sec.gov. In addition, investors will be able to obtain free copies of these documents from Revance by going to the Revance Investor Relations web page at https://investors.revance.com/ and clicking on the link titled “Financials and Filings” or by contacting Revance’s Investor Relations group at the following: Revance Therapeutics, Inc.:, Jeanie Herbert, 714-325-3584, jherbert@revance.com or Gilmartin Group, LLC.:, Laurence Watts, 619-916-7620, laurence@gilmartinir.com Participants in the Solicitation The respective directors and executive officers of Revance and HintMD may be deemed to be participants in the solicitation of written consents from the securityholders of HintMD in connection with the proposed transaction. Information regarding the interests of these directors and executive officers in the transaction described herein will be included in the prospectus/information statement described above. Additional information regarding Revance’s directors and executive officers is included in Revance’s proxy statement for its Annual Meeting of Stockholders, which was filed with the SEC on March 26, 2020. This document is available from Revance free of charge as described in the preceding paragraph. No Offer or Solicitation This communication is not intended to and shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote of approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended. 2

Acquisition would provide REVANCE access to $500M+ opportunity in payment services from $56B aesthetics annual payment processing market Data on File, IBIS, ISAPS, AmSpa 3Acquisition would provide REVANCE access to $500M+ opportunity in payment services from $56B aesthetics annual payment processing market Data on File, IBIS, ISAPS, AmSpa 3

Strategic Acquisition Would Augment Revance’s Strong Aesthetic Product Portfolio with Innovative FinTech Platform Powering Prestige DaxibotulinumtoxinA Practice and for Injection Patient Experiences PRODUCTS SERVICES Vertically-integrated Patient subscriptions and Advances Revance’s vision payments platform for practice loyalty programs to improve outcomes for medical aesthetic practices improve practice economics patients and practices 4 RHA® is a trademark of TEOXANE SA.Strategic Acquisition Would Augment Revance’s Strong Aesthetic Product Portfolio with Innovative FinTech Platform Powering Prestige DaxibotulinumtoxinA Practice and for Injection Patient Experiences PRODUCTS SERVICES Vertically-integrated Patient subscriptions and Advances Revance’s vision payments platform for practice loyalty programs to improve outcomes for medical aesthetic practices improve practice economics patients and practices 4 RHA® is a trademark of TEOXANE SA.

HintMD’s Integrated Platform Transforms Revance’s Commercial Footprint in Aesthetics Creates near-term value Leverages commercial with recurring revenue infrastructure Adds experienced fintech talent to: Aligns with Revance’s vision to • Expand our digital capabilities build a prestige aesthetics franchise that transforms patients • Address practice and patient desires for a and practice experiences loyalty program • Add features and capabilities to the platform over time 5HintMD’s Integrated Platform Transforms Revance’s Commercial Footprint in Aesthetics Creates near-term value Leverages commercial with recurring revenue infrastructure Adds experienced fintech talent to: Aligns with Revance’s vision to • Expand our digital capabilities build a prestige aesthetics franchise that transforms patients • Address practice and patient desires for a and practice experiences loyalty program • Add features and capabilities to the platform over time 5

INTEGRATED PAYMENTS MARKETS OVERVIEW 6INTEGRATED PAYMENTS MARKETS OVERVIEW 6

Fintech Industry Trends: Convergence of Software & Payments Provides businesses with the tools to drive growth, scale operations and gain insights SEAMLESS INTEGRATION IMPROVE INSIGHTS GENERATE SALES STREAMLINE BUSINESS & ANALYTICS Online Booking Software Payment Acceptance Customer Retention Tools Lead Generation Solutions Recurring Billing & e-Invoicing Business Intelligence Email Marketing Management Software Marketing Automation Website Builder CRM Reputation Management 7Fintech Industry Trends: Convergence of Software & Payments Provides businesses with the tools to drive growth, scale operations and gain insights SEAMLESS INTEGRATION IMPROVE INSIGHTS GENERATE SALES STREAMLINE BUSINESS & ANALYTICS Online Booking Software Payment Acceptance Customer Retention Tools Lead Generation Solutions Recurring Billing & e-Invoicing Business Intelligence Email Marketing Management Software Marketing Automation Website Builder CRM Reputation Management 7

Vertically-Integrated Payment Platforms are Disrupting Traditional Markets Restaurant Management 1 Spa & Fitness 2 Platform $1.9 Billion 2020 Valuation $4.9 Billion Acquired by Vista Partners 2019 Forbes Fintech 50 - Point-of-Sale Technology Platform - Point-of-Sale Purchases Integrated Technology Platform - Online Ordering Payments - Recurring Memberships Streamlining Restaurant - Email Marketing Key to Value - Web & Mobile Sales Operations Proposition - Guest Facing Technology - MINDBODY App Promotional Sales - Payroll and Team Management - Network Partner Sales - Customer Success Team 1. Vista Equity Partners & Mindbody Press Release: https://company.mindbodyonline.com/press/vista-equity-partners-completes-acquisition-of-mindbody-inc 8 2. Toast Press Release: https://www.reuters.com/article/us-toast-funding/restaurant-software-maker-toast-valued-at-4-9-billion-after-latest-funding-round-idUSKBN20829J, https://pos.toasttab.com/aboutVertically-Integrated Payment Platforms are Disrupting Traditional Markets Restaurant Management 1 Spa & Fitness 2 Platform $1.9 Billion 2020 Valuation $4.9 Billion Acquired by Vista Partners 2019 Forbes Fintech 50 - Point-of-Sale Technology Platform - Point-of-Sale Purchases Integrated Technology Platform - Online Ordering Payments - Recurring Memberships Streamlining Restaurant - Email Marketing Key to Value - Web & Mobile Sales Operations Proposition - Guest Facing Technology - MINDBODY App Promotional Sales - Payroll and Team Management - Network Partner Sales - Customer Success Team 1. Vista Equity Partners & Mindbody Press Release: https://company.mindbodyonline.com/press/vista-equity-partners-completes-acquisition-of-mindbody-inc 8 2. Toast Press Release: https://www.reuters.com/article/us-toast-funding/restaurant-software-maker-toast-valued-at-4-9-billion-after-latest-funding-round-idUSKBN20829J, https://pos.toasttab.com/about

Delivering Prestige Patient and Practice Experience Through Vertically- Integrated Payments Platform For Aesthetic Practices Practice eCommerce/ Loyalty Logistics Rewards Patient Patient Wallet Brand Reward Lending With Practice Points + Cards Payment Patient Terminal Lending In-Practice Patient Marketing + Subscriptions Lead Gen 1+ Analytics, Point-of-Sale Inventory, EMR Practice Loyalty Payments Scheduling Program Conventional Experience Experience Multiple Points of Engagement Single Point of Engagement 9Delivering Prestige Patient and Practice Experience Through Vertically- Integrated Payments Platform For Aesthetic Practices Practice eCommerce/ Loyalty Logistics Rewards Patient Patient Wallet Brand Reward Lending With Practice Points + Cards Payment Patient Terminal Lending In-Practice Patient Marketing + Subscriptions Lead Gen 1+ Analytics, Point-of-Sale Inventory, EMR Practice Loyalty Payments Scheduling Program Conventional Experience Experience Multiple Points of Engagement Single Point of Engagement 9

HintMD’s Investment in PCI Compliance* and PayFac Enables Competitive Advantage in the Aesthetics Market Payment Facilitators (PayFac) manage merchant underwriting Begin accepting PCI compliant Fraud control payments process, risk management, and immediately payment processing – enabling innovation within industry verticals which delivers competitive advantage and offers incremental value to platform Compliance requirements PayFac enables patient managed by HintMD level data insights customers * PCI DSS – Payment card industry data security standard 10HintMD’s Investment in PCI Compliance* and PayFac Enables Competitive Advantage in the Aesthetics Market Payment Facilitators (PayFac) manage merchant underwriting Begin accepting PCI compliant Fraud control payments process, risk management, and immediately payment processing – enabling innovation within industry verticals which delivers competitive advantage and offers incremental value to platform Compliance requirements PayFac enables patient managed by HintMD level data insights customers * PCI DSS – Payment card industry data security standard 10

Controlling More of the Payments Chain Strengthens HintMD’s Offering 2.87 – 4.35% Avg. fee per transac7on 3 0.5 - 1% Practice Cost Reseller Fees Gateway Fees Risk Management Processor Fees Card Brand Fees Issuer Fees Fees 3 0.5 - 1% 1. https://squareup.com/guides/credit-card-processing-fees-and-rates 11 2. Data on file, IBIS, ISAPS, AmSpa 3. Data on file HINTMD Conventional Value Chain Value ChainControlling More of the Payments Chain Strengthens HintMD’s Offering 2.87 – 4.35% Avg. fee per transac7on 3 0.5 - 1% Practice Cost Reseller Fees Gateway Fees Risk Management Processor Fees Card Brand Fees Issuer Fees Fees 3 0.5 - 1% 1. https://squareup.com/guides/credit-card-processing-fees-and-rates 11 2. Data on file, IBIS, ISAPS, AmSpa 3. Data on file HINTMD Conventional Value Chain Value Chain

U.S. Market Opportunity – Aesthetics Payment Processing in 2019 33k Aesthetics practices in the U.S. $500+ $56 Billion Million Annual Payment Revenue Opportunity Processing Opportunity in U.S. Aesthetic Payment Services $1.7M Average revenue per year 12 Data on file, IBIS, ISAPS, AmSpaU.S. Market Opportunity – Aesthetics Payment Processing in 2019 33k Aesthetics practices in the U.S. $500+ $56 Billion Million Annual Payment Revenue Opportunity Processing Opportunity in U.S. Aesthetic Payment Services $1.7M Average revenue per year 12 Data on file, IBIS, ISAPS, AmSpa

Physician Research Shows Strong Interest in FINTECH Platform – New Payment and Loyalty Solutions 64% 2x 90% Would consider/ ready to Increase in visits due to Value automated brand switch due to pricing or subscriptions loyalty as a major integration value driver Previously, payment solutions and brand loyalty programs were all “ separate processes in my practice. By adding HintMD’s platform, we have streamlined our practice operations and improved our patient experience. Additionally, by adding HintMD’s subscriptions, our annual injectable revenue has increased by almost $1,000 per patient. ” Grant Stevens, M.D , F.A.C.S. 13 Data on filePhysician Research Shows Strong Interest in FINTECH Platform – New Payment and Loyalty Solutions 64% 2x 90% Would consider/ ready to Increase in visits due to Value automated brand switch due to pricing or subscriptions loyalty as a major integration value driver Previously, payment solutions and brand loyalty programs were all “ separate processes in my practice. By adding HintMD’s platform, we have streamlined our practice operations and improved our patient experience. Additionally, by adding HintMD’s subscriptions, our annual injectable revenue has increased by almost $1,000 per patient. ” Grant Stevens, M.D , F.A.C.S. 13 Data on file

OVERVIEW 14OVERVIEW 14

From Dynamic Subscriptions to a Vertically-Integrated Payments Platform Dynamic Subscriptions PC/HintMini Point-of-Sale Launched subscriptions for Launched full Released during services & skincare Point-of-Sale ASAPS 2019 Founding Hint, Inc. founded in Payments Brand Rewards Full Commercial Silicon Valley, California Development Launched Brilliant Platform & Integrated Launch Distinctions® Integration Partners 2015 2016 2017 2018 2019 2020 2021 PayFac Patient App underwritten by Visa, MasterCard, and FiServ Launched Patient APP to follow Treatment Plan Proof-of-Concept Allergan Investment Patient Wallet Launch POC platform to to develop Brilliant Distinctions® Launch Ready test in-practice aesthetic rewards automation skincare subscriptions 15 * Brilliant Distinctions® is a registered trademarks of AllerganFrom Dynamic Subscriptions to a Vertically-Integrated Payments Platform Dynamic Subscriptions PC/HintMini Point-of-Sale Launched subscriptions for Launched full Released during services & skincare Point-of-Sale ASAPS 2019 Founding Hint, Inc. founded in Payments Brand Rewards Full Commercial Silicon Valley, California Development Launched Brilliant Platform & Integrated Launch Distinctions® Integration Partners 2015 2016 2017 2018 2019 2020 2021 PayFac Patient App underwritten by Visa, MasterCard, and FiServ Launched Patient APP to follow Treatment Plan Proof-of-Concept Allergan Investment Patient Wallet Launch POC platform to to develop Brilliant Distinctions® Launch Ready test in-practice aesthetic rewards automation skincare subscriptions 15 * Brilliant Distinctions® is a registered trademarks of Allergan

HintMD will Power Prestige Patient Experiences in Aesthetic Practices Today and in the Future HINTMD Platform HINTMD Platform HINTMD Platform Pa0ent Wallet Prac0ce Custom Loyalty eCommerce Shipping HINTMD Platform HINTMD PARTNERS* Brand Loyalty Insights & Programs SUBSCRIPTIONS Analy0cs & PRACTICE HINTMD PARTNERS* HINTMD Platform LOYALTY EMR / Prac0ce Subscriptions SMART Management PARTNER PAYMENTS INTEGRATIONS HINTMD Platform PLATFORM HINTMD PARTNERS* Installments Pa0ent Lending HINTMD Platform HINTMD PARTNERS* Point-of-Sale Marke0ng & (No-Touch) Lead Genera0on 16 16 * Future – in progressHintMD will Power Prestige Patient Experiences in Aesthetic Practices Today and in the Future HINTMD Platform HINTMD Platform HINTMD Platform Pa0ent Wallet Prac0ce Custom Loyalty eCommerce Shipping HINTMD Platform HINTMD PARTNERS* Brand Loyalty Insights & Programs SUBSCRIPTIONS Analy0cs & PRACTICE HINTMD PARTNERS* HINTMD Platform LOYALTY EMR / Prac0ce Subscriptions SMART Management PARTNER PAYMENTS INTEGRATIONS HINTMD Platform PLATFORM HINTMD PARTNERS* Installments Pa0ent Lending HINTMD Platform HINTMD PARTNERS* Point-of-Sale Marke0ng & (No-Touch) Lead Genera0on 16 16 * Future – in progress

Simple. Seamless. Smart - Point of Sale System that Delivers Touchless benefits of smart payments HintMD enables practices to complete checkout with no contact needed between your patients and staff. • Front Desk Simple • In Treatment Rooms Checkout Options • Remotely Our partnership with HintMD simplified my prac7ce, gave us evenly “ distributed cash flow, no more late-night cosme7c events, a?racted new pa7ents and happier exis7ng pa7ents returning on schedule. During the COVID crisis, HintMD’s pa7ent subscrip7ons provided much needed cash flow helping my prac7ce through the shutdown. Robert Beer M.D. ” Balfour Dermatology 17Simple. Seamless. Smart - Point of Sale System that Delivers Touchless benefits of smart payments HintMD enables practices to complete checkout with no contact needed between your patients and staff. • Front Desk Simple • In Treatment Rooms Checkout Options • Remotely Our partnership with HintMD simplified my prac7ce, gave us evenly “ distributed cash flow, no more late-night cosme7c events, a?racted new pa7ents and happier exis7ng pa7ents returning on schedule. During the COVID crisis, HintMD’s pa7ent subscrip7ons provided much needed cash flow helping my prac7ce through the shutdown. Robert Beer M.D. ” Balfour Dermatology 17

Consumer Interest in Aesthetics Subscriptions is High Aesthetic subscriptions are broadly appealing, with an even distribution of interest across ages and incomes of aesthetics consumers patients participate interested in 33% 52% in some kind of aesthetic 1 1 subscription subscriptions 1. The American Society of Plastic Surgeons. 2018 Plastic Surgery Statistic Report. Available at: https://www.plasticsurgery.org/documents/News/Statistics/2018/plastic-surgery-statistics-full-report-2018.pdf. Accessed July 2019 18 Subscription defined as recurring billing process for regular, repeated treatments at a practice. , Data on FileConsumer Interest in Aesthetics Subscriptions is High Aesthetic subscriptions are broadly appealing, with an even distribution of interest across ages and incomes of aesthetics consumers patients participate interested in 33% 52% in some kind of aesthetic 1 1 subscription subscriptions 1. The American Society of Plastic Surgeons. 2018 Plastic Surgery Statistic Report. Available at: https://www.plasticsurgery.org/documents/News/Statistics/2018/plastic-surgery-statistics-full-report-2018.pdf. Accessed July 2019 18 Subscription defined as recurring billing process for regular, repeated treatments at a practice. , Data on File

Dynamic Subscriptions - Grow Recurring Revenue Through Increased Patient Compliance & Loyalty Provides an opportunity to create practice-centric loyalty programs 85% of practices believe subscriptions are an important/very important value driver Subscription patients visit 50-100% more frequently than non- subscribers Subscription patients spend 25-50% more per year than non-subscribers Patient treatment plans can be personalized into dynamic subscriptions with flexibility across brands and frequencies Enables practices to deliver custom practice loyalty programs to patients Data on file 19Dynamic Subscriptions - Grow Recurring Revenue Through Increased Patient Compliance & Loyalty Provides an opportunity to create practice-centric loyalty programs 85% of practices believe subscriptions are an important/very important value driver Subscription patients visit 50-100% more frequently than non- subscribers Subscription patients spend 25-50% more per year than non-subscribers Patient treatment plans can be personalized into dynamic subscriptions with flexibility across brands and frequencies Enables practices to deliver custom practice loyalty programs to patients Data on file 19

Third-Party Integration via Open Platform Skincare Products Partner Integration • Payment processing provides access to real-time structured data Loyalty Programs enabling brand reward automation • Streamlines reconciliation and reduces burden on staff resources • Practice-level sell-through data provides real-time feedback on brand Service Providers promotions *The above skincare products, loyalty programs and service providers are registered 20 trademarks of their respective companies.Third-Party Integration via Open Platform Skincare Products Partner Integration • Payment processing provides access to real-time structured data Loyalty Programs enabling brand reward automation • Streamlines reconciliation and reduces burden on staff resources • Practice-level sell-through data provides real-time feedback on brand Service Providers promotions *The above skincare products, loyalty programs and service providers are registered 20 trademarks of their respective companies.

Revenue Drivers for Revance with HintMD GROWT H DRIV ERS REV ANCE OP P OR T U N IT IE S Increasing spend in the medical aesthetic industry will drive new # US practices Smart practice openings and total revenue available for processing point-of-sale (Payment % credit card Consumers will continue to transition to credit, resulting in a Processing) transactions growing share of spend going through payment processors Growing acceptance regarding medical aesthetic treatments Opportunities # Medical aesthetic will drive growth in number of patients receiving treatments to enhance patients practice-to- Subscription Enhanced awareness of subscription payment options will patient value adoption drive a larger portion of consumers to adopt over time Increasing spend in the medical aesthetic industry will drive new # US practices Integrated practice openings and expand account base for software sales and innovative Consumers have come to expect rewards programs to be available Loyalty adoption solutions across all channels where they shop, including medical aesthetics 21 Data on file, IBIS, ISAPS, AmSpa,Revenue Drivers for Revance with HintMD GROWT H DRIV ERS REV ANCE OP P OR T U N IT IE S Increasing spend in the medical aesthetic industry will drive new # US practices Smart practice openings and total revenue available for processing point-of-sale (Payment % credit card Consumers will continue to transition to credit, resulting in a Processing) transactions growing share of spend going through payment processors Growing acceptance regarding medical aesthetic treatments Opportunities # Medical aesthetic will drive growth in number of patients receiving treatments to enhance patients practice-to- Subscription Enhanced awareness of subscription payment options will patient value adoption drive a larger portion of consumers to adopt over time Increasing spend in the medical aesthetic industry will drive new # US practices Integrated practice openings and expand account base for software sales and innovative Consumers have come to expect rewards programs to be available Loyalty adoption solutions across all channels where they shop, including medical aesthetics 21 Data on file, IBIS, ISAPS, AmSpa,

INTEGRATION / DEAL TERMS 22INTEGRATION / DEAL TERMS 22

HintMD Integration Revance Future Footprint Access to technology talent, which will remain as a cohesive team Combines current Revance sales force with HintMD specialists as technical experts Pleasanton Synergize across commercial, (Technology) Newark G&A and non-technology functions (HQ + Operations) Centers of excellence with technology hubs in the San Francisco Bay Area and a commercial hub Irvine in Irvine. (Commercial) 23 23HintMD Integration Revance Future Footprint Access to technology talent, which will remain as a cohesive team Combines current Revance sales force with HintMD specialists as technical experts Pleasanton Synergize across commercial, (Technology) Newark G&A and non-technology functions (HQ + Operations) Centers of excellence with technology hubs in the San Francisco Bay Area and a commercial hub Irvine in Irvine. (Commercial) 23 23

Revance Commercial Launch Cadence Prestige Education and Training Consumer Digital & Program for select practices DTC Push DaxibotulinumtoxinA for Injection Anticipated PDUFA Prestige Education and Training th Nov 25 Program for select practices Q3 Q4 Q1 Q2 2020 2020 2021 2021 Build install base by launching Expand HintMD launch Acquisition announced Anticipated platform to RVNC KOLs with RVNC salesforce deal close & integration 24 Services Products DaxibotulinumtoxinA for Injection Uniting Innovative Products and Digital ServicesRevance Commercial Launch Cadence Prestige Education and Training Consumer Digital & Program for select practices DTC Push DaxibotulinumtoxinA for Injection Anticipated PDUFA Prestige Education and Training th Nov 25 Program for select practices Q3 Q4 Q1 Q2 2020 2020 2021 2021 Build install base by launching Expand HintMD launch Acquisition announced Anticipated platform to RVNC KOLs with RVNC salesforce deal close & integration 24 Services Products DaxibotulinumtoxinA for Injection Uniting Innovative Products and Digital Services

Key Financial Highlights and Key Business Terms HintMD currently installed in ~175 pilot practices 2019 Revenue $1.4M Stock-for-stock Non-cash Management team Intention to nominate business investment of 8.54 and directors subject to Co-Founder and CEO, combination million shares lockup agreements Aubrey Rankin, for election to the RVNC Board upon close 25 Deal is subject to Hint, Inc. shareholder approval Key Financial Highlights and Key Business Terms HintMD currently installed in ~175 pilot practices 2019 Revenue $1.4M Stock-for-stock Non-cash Management team Intention to nominate business investment of 8.54 and directors subject to Co-Founder and CEO, combination million shares lockup agreements Aubrey Rankin, for election to the RVNC Board upon close 25 Deal is subject to Hint, Inc. shareholder approval

Revance Financial Overview and Updated 2020 Guidance Cash runway unchanged into 2023 $511M $220 to $230M Cash, cash equivalents and FY 2020 Non-GAAP 1 short-term investments Operating Expense 1. As of March 31, 2020, unaudited, See “Use of Non-GAAP Financial Measures” in press release entitled “Revance Reports First Quarter 2020 Financial Results and Provides Corporate Update” issued by Revance on May 7, 2020 26 Because of this transaction, the GAAP operating expenses will not be in the previously provided range, but cannot be estimated at this time.Revance Financial Overview and Updated 2020 Guidance Cash runway unchanged into 2023 $511M $220 to $230M Cash, cash equivalents and FY 2020 Non-GAAP 1 short-term investments Operating Expense 1. As of March 31, 2020, unaudited, See “Use of Non-GAAP Financial Measures” in press release entitled “Revance Reports First Quarter 2020 Financial Results and Provides Corporate Update” issued by Revance on May 7, 2020 26 Because of this transaction, the GAAP operating expenses will not be in the previously provided range, but cannot be estimated at this time.

Daring to make a difference with products, and now services, delivering meaningful outcomes to our customers 27 27Daring to make a difference with products, and now services, delivering meaningful outcomes to our customers 27 27

THANK YOU 28THANK YOU 28

Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Jun 2024 to Jul 2024

Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Jul 2023 to Jul 2024